Dr. Markovic is currently Senior Director, Head of US & EU, Pharma Technical Regulatory Policy, at Genentech, A Member of the Roche Group. In this role, she is responsible for general advocacy, outreach, and benchmarking efforts. Ingrid represents Genentech in PhRMa and BIO Manufacturing committees, USP, and supports BIO delegation in ICH Management Committee and Assembly. Ingrid also serves on Genentech strategic regulatory governance/oversight teams with a special focus on Emerging Technology and New Therapeutic Modalities. Prior to this, she held several positions of increasing responsibility at U.S. FDA, CDER and CBER. Her last position was Senior Science Advisor for CMC in the immediate Office of the Center Director at CBER. In this role, Ingrid was responsible for center-level CMC regulatory policy development, implementation and integration. She additionally served as FDA/CBER ICH Quality Lead and was FDA topic (co)lead on ICH Q12 Expert Working Group. Ingrid trained in Biochemistry, Biophysics and Natural Products Chemistry. She holds a Ph.D. degree from University of Wisconsin, Madison and completed her post-doctoral training at U.S. National Institutes of Health in Bethesda, MD.